On the efficiency of targeted clinical trials
- PMID: 15551403
- DOI: 10.1002/sim.1975
On the efficiency of targeted clinical trials
Abstract
The development of genomics-based technologies is demonstrating that many common diseases are heterogeneous collections of molecularly distinct entities. Molecularly targeted therapeutics is often effective only for some subsets patients with a conventionally defined disease. We consider the problem of design of phase III randomized clinical trials for the evaluation of a molecularly targeted treatment when there is an assay predictive of which patients will be more responsive to the experimental treatment than to the control regimen. We compare the conventional randomized clinical trial design to a design based on randomizing only patients predicted to preferentially benefit from the new treatment. Trial designs are compared based on the required number of randomized patients and the expected number of patients screened for randomization eligibility. Relative efficiency depends upon the distribution of treatment effect across patient subsets, prevalence of the subset of patients who respond preferentially to the experimental treatment, and assay performance.
Copyright 2004 John Wiley & Sons, Ltd.
Similar articles
-
Evaluating the efficiency of targeted designs for randomized clinical trials.Clin Cancer Res. 2004 Oct 15;10(20):6759-63. doi: 10.1158/1078-0432.CCR-04-0496. Clin Cancer Res. 2004. PMID: 15501951
-
Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.Clin Cancer Res. 2005 Nov 1;11(21):7872-8. doi: 10.1158/1078-0432.CCR-05-0605. Clin Cancer Res. 2005. PMID: 16278411
-
Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset.Pharm Stat. 2007 Jul-Sep;6(3):227-44. doi: 10.1002/pst.300. Pharm Stat. 2007. PMID: 17688238
-
[Phase III trials in oncology].Bull Cancer. 1999 Feb;86(2):143-7. Bull Cancer. 1999. PMID: 10066944 Review. French.
-
Design and endpoints of clinical trials in hepatocellular carcinoma.J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13. J Natl Cancer Inst. 2008. PMID: 18477802 Review.
Cited by
-
Fool's gold, lost treasures, and the randomized clinical trial.BMC Cancer. 2013 Apr 16;13:193. doi: 10.1186/1471-2407-13-193. BMC Cancer. 2013. PMID: 23587187 Free PMC article.
-
Adjusting for misclassification in a stratified biomarker clinical trial.Stat Med. 2014 Aug 15;33(18):3100-13. doi: 10.1002/sim.6164. Epub 2014 Apr 14. Stat Med. 2014. PMID: 24733510 Free PMC article.
-
Auxiliary variable-enriched biomarker-stratified design.Stat Med. 2018 Dec 30;37(30):4610-4635. doi: 10.1002/sim.7938. Epub 2018 Sep 16. Stat Med. 2018. PMID: 30221368 Free PMC article.
-
Drug-diagnostics co-development in oncology.Front Oncol. 2013 Dec 23;3:315. doi: 10.3389/fonc.2013.00315. Front Oncol. 2013. PMID: 24392354 Free PMC article. Review.
-
Genomic advances and their impact on clinical trial design.Genome Med. 2009 Jul 13;1(7):69. doi: 10.1186/gm69. Genome Med. 2009. PMID: 19638184 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources